These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1396108)

  • 41. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.
    Baker JR; Best AM; Pade PA; McCance-Katz EF
    Ann Pharmacother; 2006 Mar; 40(3):392-6. PubMed ID: 16507617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia.
    Pick CG; Peter Y; Schreiber S; Weizman R
    Brain Res; 1997 Jan; 744(1):41-6. PubMed ID: 9030411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand.
    Robinson GM; Dukes PD; Robinson BJ; Cooke RR; Mahoney GN
    Drug Alcohol Depend; 1993 Jun; 33(1):81-6. PubMed ID: 8370341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine and gastrointestinal transit in rats: effect of naloxone on the biphasic dose-response curve.
    Cowan A
    Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):47-9. PubMed ID: 1623635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users.
    Levy-Cooperman N; Schoedel KA; Reiz JL; Thompson D; Chakaraborty B; Geoffroy P; Michalko KJ
    J Opioid Manag; 2016; 12(3):165-80. PubMed ID: 27435437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Negative reinforcing properties of naloxone in the non-dependent rhesus monkey: influence on reinforcing properties of codeine, tilidine, buprenorphine, and pentazocine.
    Hoffmeister F
    Psychopharmacology (Berl); 1986; 90(4):441-50. PubMed ID: 3101099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of naloxone with buprenorphine in humans.
    Weinhold LL; Bigelow GE; Preston KL
    NIDA Res Monogr; 1989; 95():485. PubMed ID: 2641039
    [No Abstract]   [Full Text] [Related]  

  • 51. Buprenorphine: bell-shaped dose-response curve for its antagonist effects.
    Lizasoain I; Leza JC; Lorenzo P
    Gen Pharmacol; 1991; 22(2):297-300. PubMed ID: 2055424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
    Stinus L; Cador M; Zorrilla EP; Koob GF
    Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine suppresses cocaine self-administration by rhesus monkeys.
    Mello NK; Mendelson JH; Bree MP; Lukas SE
    Science; 1989 Aug; 245(4920):859-62. PubMed ID: 2772637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of buprenorphine on fentanyl withdrawal in rats.
    Bruijnzeel AW; Marcinkiewcz C; Isaac S; Booth MM; Dennis DM; Gold MS
    Psychopharmacology (Berl); 2007 May; 191(4):931-41. PubMed ID: 17211652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
    Walsh SL; Preston KL; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.